Literature DB >> 3295765

Variability in drug metabolism: importance of genetic constitution.

J H Schellens, D D Breimer.   

Abstract

In man wide variability exists in the rate of metabolism of drugs and among factors which contribute to this phenomenon genetic constitution is of major importance. The metabolism of a number of drugs is subject to polymorphism and the frequency distribution of particular pharmacokinetic parameters shows bimodality, with poor (PM) and extensive metabolizers (EM). Acetylation of a number of drugs is known to be polymorphic and the incidence of poor metabolizers varies markedly among different populations. Debrisoquine and sparteine are frequently applied model substrates for the characterization of a polymorphism in oxidative metabolism. Polymorphic drug oxidation may have important clinical implications, because when standard dosage regimens are applied plasma concentrations will reach far above the maximum acceptable in poor metabolizers and consequently side effects may arise. Regarding the multiplicity of the drug oxidizing enzyme system (cytochrome P-450) it could be of interest to combine model substrates in a cocktail to be able to characterize human subjects simultaneously for a number of independent polymorphisms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3295765     DOI: 10.1007/BF01960741

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  28 in total

1.  Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction.

Authors:  T Shimada; K S Misono; F P Guengerich
Journal:  J Biol Chem       Date:  1986-01-15       Impact factor: 5.157

2.  Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.

Authors:  P R Jackson; G T Tucker; M S Lennard; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

3.  The genetic polymorphism of sparteine metabolism.

Authors:  M Eichelbaum; K P Reetz; E K Schmidt; C Zekorn
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

4.  Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers.

Authors:  P Dayer; R Gasser; J Gut; T Kronbach; G M Robertz; M Eichelbaum; U A Meyer
Journal:  Biochem Biophys Res Commun       Date:  1984-11-30       Impact factor: 3.575

5.  Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.

Authors:  L Bertilsson; H J Dengler; M Eichelbaum; H U Schulz
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

6.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

7.  Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.

Authors:  J C McGourty; J H Silas; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

8.  Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.

Authors:  M Eichelbaum; N M Woolhouse
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation.

Authors:  A O Iyun; M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacol Ther       Date:  1986-10       Impact factor: 6.875

10.  Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.

Authors:  M S Lennard; G T Tucker; J H Silas; H F Woods
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

View more
  1 in total

1.  Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.

Authors:  R J Guttendorf; M Britto; R A Blouin; T S Foster; W John; K A Pittman; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.